Board MeetingMay 13, 2026, 08:06 AM
Candel Therapeutics CEO to Present at Stifel & Jefferies Conferences
AI Summary
Candel Therapeutics, Inc. announced that its President and CEO, Paul Peter Tak, will present and participate in one-on-one meetings with investors at two upcoming conferences. He will speak at the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies for cancer, with lead product candidates aglatimagene besadenovec (CAN-2409) and linoserpaturev (CAN-3110) in clinical development.
Key Highlights
- Candel Therapeutics CEO Paul Peter Tak to present at Stifel 2026 Virtual Targeted Oncology Forum.
- Stifel presentation scheduled for Wednesday, May 20, 2026, at 10 AM ET.
- CEO to also present at the Jefferies Global Healthcare Conference.
- Jefferies presentation scheduled for Wednesday, June 3, 2026, at 5:30 PM ET.
- Company is a clinical-stage biopharmaceutical firm developing cancer immunotherapies.
- Lead candidate aglatimagene (CAN-2409) has Fast Track, RMAT, and Orphan Drug designations.
- Linoserpaturev (CAN-3110) is in an ongoing Phase 1b clinical trial.
Price Impact
More from CADL